AI SummaryDecoy20, a bacterial product, showed promising preliminary results in a Phase 1 trial for advanced/metastatic solid tumors. The study demonstrated transient immune activation and stable disease in patients. This supports the hypothesis that Decoy products can be used as monotherapy or in combination with approved agents.Background Systemic activation of multiple immune receptors, such as… Continue reading 782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors
Tag: Biochemical Pharmacology
782-I Phase I dose escalation of SAR445710, a PDL1-IL15 targeted cytokine in metastatic and/or advanced solid tumors
Background SAR445710 is a targeted cytokine comprised of a fusion antibody combining a fully human, high affinity anti-human Programmed Death Ligand 1 (PD-L1) IgG1 antibody with the human IL-15 receptor alpha (IL-15Rα) sushi domain and human IL-15. SAR445710 and its mouse cross-reactive surrogate molecule have been extensively characterized by in vitro and in vivo studies… Continue reading 782-I Phase I dose escalation of SAR445710, a PDL1-IL15 targeted cytokine in metastatic and/or advanced solid tumors
222-I A single-domain antibody-based PET tracer to visualize human CD4-positive cells in vivo
AI SummaryResearchers have developed a PET tracer called 64Cu-αCD4-sdAb that can detect small amounts of CD4+ cells in cancer and inflammation. The tracer shows potential for use in imaging and monitoring T cell-associated diseases.Background CD4+ T cells play essential roles in the development and regulation of autoimmune diseases and cancer. Recently, we have developed single-domain… Continue reading 222-I A single-domain antibody-based PET tracer to visualize human CD4-positive cells in vivo
1201-A An antibody-drug conjugate selectively targeting a GSTA glycosite-signature neoantigen epitope of MUC1 in cancer cells with COSMC deficiency
Background Antibodies targeting aberrantly glycosylated proteins are ineffective in treating cancer. Antibody-drug conjugates have emerged as effective alternatives, facilitating tumor-specific drug delivery. Previous studies have assessed the aberrantly glycosylated tandem repeat region of MUC1 glycoprotein as three site-specific glycosylated neoantigen peptide motifs (PDTR, GSTA, and GVTS) for binding with a monoclonal antibody.1 2 Neoantigen epitopes… Continue reading 1201-A An antibody-drug conjugate selectively targeting a GSTA glycosite-signature neoantigen epitope of MUC1 in cancer cells with COSMC deficiency
442-F Optimization of a human scFv-based PSMA-CAR T cell therapy for the treatment of metastatic castration-resistant prostate cancer
AI SummaryA study discusses the development of a fully human scFv-based PSMA-CAR for treating mCRPC. Various optimizations were made, including the addition of a novel membrane-bound IL-12 molecule. The optimized hPSMA-CAR showed improved stability and activity, but its polyfunctionality was suboptimal compared to J591 CAR. However, the addition of mbIL12 increased expansion, cytokine secretion, and… Continue reading 442-F Optimization of a human scFv-based PSMA-CAR T cell therapy for the treatment of metastatic castration-resistant prostate cancer
1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
Background Immune checkpoint blockade is effective for a subset of patients across many cancers, but most patients are refractory to current immunotherapies and new approaches are needed to overcome resistance.1 2 The protein tyrosine phosphatase PTPN2 and the closely related PTPN1 are central regulators of inflammation, and their genetic deletion in either tumor cells or… Continue reading 1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
442-M Tumor targeted, adipose-derived human mast cells have anti-tumor effects in vivo after intravenous injection
Background The use of one’s own cells to treat tumors is typified by chimeric antigen receptor T cells (CAR T) therapy yet cells with anti-tumor properties being investigated continues to grow. We have previously proposed a new strategy using tumor-targeted mast cells (MC) obtained from autologous sources and demonstrated proof-of concept previously in vitro and… Continue reading 442-M Tumor targeted, adipose-derived human mast cells have anti-tumor effects in vivo after intravenous injection
MO2-4 Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in older adults aged over 75 years
Pembrolizumab (Pemb) is a key drug for the treatment of advanced or recurrent non-small cell lung cancer (NSCLC). However, there are limited data on Pemb use in older adults aged >75 years with NSCLC, especially in terms of pharmacokinetics (PK).
From the Bench: Creative Approaches in Cancer Research, Fall 2023
For our readers who enjoy learning about the newest tools and strategies in cancer research, the second installment of our series, “From the Bench,” is here. (Check out the inaugural post here.) This quarter, we bring you engineered bacteria that detect cancer or tag cancer cells for recognition by immune cells, a strategy to rewire… Continue reading From the Bench: Creative Approaches in Cancer Research, Fall 2023